ID   SpESFX-2
AC   CVCL_WS51
SY   SpESF-X2; SpESFX clone 2
DR   Wikidata; Q98132817
RX   Patent=US7608425;
CC   Group: Hybridoma fusion partner cell line.
CC   Group: Patented cell line.
CC   Group: Serum/protein free medium cell line.
CC   Characteristics: Transfected with a hBCL2-EEE-pZeoSV2+ construct.
CC   Selected for resistance to: ChEBI; CHEBI_63486; 8-azaguanine.
CC   Genetic integration: Method=Transfection/transduction; Gene=HGNC; HGNC:990; BCL2 (Note=With p.Thr69Glu, p.Ser70Glu and p.Ser87Glu = BCL2-EEE).
CC   Genetic integration: Method=Transfection/transduction; Gene=UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR).
CC   Cell type: Plasma cell; CL=CL_0000786.
CC   Breed/subspecies: BALB/c.
DI   NCIt; C125417; Mouse multiple myeloma
OX   NCBI_TaxID=10090; ! Mus musculus (Mouse)
HI   CVCL_WS49 ! SpESFX
SX   Female
AG   Age unspecified
CA   Cancer cell line
DT   Created: 05-07-19; Last updated: 14-08-25; Version: 8
//
RX   Patent=US7608425;
RA   Goldenberg, David M.
RA   Chang, Chien-Hsing
RA   Rossi, Edmund A.
RA   Nordstrom, Diane
RT   "Methods for protein expression in mammalian cells in serum-free
RT   medium.";
RL   Patent number US7608425, 27-Oct-2009.
//